GLP-1
Bridge Biotherapeutics licensed out its BB-877 to Boehringer Ingelheim for a total deal of about $1.75 billion. This is the second large deal for fibrotic diseases Boehringer Ingelheim inked since the beginning of the month.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos’ pipeline.
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided an update on the progress of the development of odevixibat for pediatric cholestatic liver diseases and elobixibat for NASH.
Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH
Companies from across the globe provide information on agreements and pipeline updates.
Contract research organization jobs may not seem as appealing as working in R&D but it can have a lot of advantages—including plenty of career opportunities.
Galapagos NV announces a share capital increase arising from warrant exercises.
The approval marks the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for children and adolescents with type 2 diabetes.
Galapagos NV received a transparency notification from The Capital Group Companies, Inc.
PRESS RELEASES